IP Library Granted Patent US 8,383,611
Granted Patent B1
US 8,383,611 · App. 10/110,632 · Granted Feb 26, 2013

Ciclesonide containing aqueous pharmaceutical composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,611
App. No.
10/110,632
Granted
Feb 26, 2013
Kind
B1
Abstract

The present invention provides an aqueous pharmaceutical composition containing ciclesonide and hydroxypropyl-methylcellulose, wherein the ciclesonide is dispersed in an aqueous medium in the form of solid particles. The composition is able to avoid variations in the concentrations of ciclesonide during production as well as avoid decreases in the recovery rate of ciclesonide.

Claims (33)

1. An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose, wherein said ciclesonide is uniformly dispersed in an aqueous medium in the form of solid particles, wherein said crystalline cellulose carmellose sodium concentration is 1.7% w/w, and wherein said hydroxypropylmethylcellulose concentration is 0.1% w/w, relative to the total amount of the composition.

2. An aqueous pharmaceutical composition according to claim 1 which further comprises one or more types of a water-insoluble substance and/or water-low soluble substance which is one or more types of cellulose.

3. An aqueous pharmaceutical composition according to claim 2 , which further comprises a water-soluble polymer substance.

4. An aqueous pharmaceutical composition according to claim 3 , wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.

5. An aqueous pharmaceutical composition according to claim 3 , wherein said water-soluble polymer substance is polyethylene glycol.

6. An aqueous pharmaceutical composition according to claim 3 , wherein said water-soluble polymer substance is hydroxypropylcellulose.

7. An aqueous pharmaceutical composition according to claim 1 which further comprises a water-soluble polymer substance.

8. An aqueous pharmaceutical composition according to claim 7 , wherein said water-soluble polymer substance is one or more types selected from the group consisting of polyethylene glycol, propylene glycol alginate, pectin, methoxyl pectin, guar gum, gum arabic, carrageenan, methylcellulose, xanthan gum and hydroxypropylcellulose.

9. An aqueous pharmaceutical composition according to claim 7 , wherein said water-soluble polymer substance is polyethylene glycol.

10. An aqueous pharmaceutical composition according to claim 7 , wherein said water-soluble polymer substance is hydroxypropylcellulose.

11. An aqueous pharmaceutical composition according to claim 1 , wherein the ciclesonide particles have a size of between about 10 nm and about 100 μm.

12. An aqueous pharmaceutical composition according to claim 1 , wherein the ciclesonide particles have a size of between about 10 nm and about 10 μm.

13. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one wetting agent.

14. An aqueous pharmaceutical composition according to claim 13 , wherein at least one wetting agent present is selected from the group consisting of Polysorbate 80, glycerin monostearate, polyoxyl stearate, lauromacrogol, sorbitan oleate and sucrose fatty acid esters.

15. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one osmotic-pressure controlling agent.

16. An aqueous pharmaceutical composition according to claim 15 , wherein at least one osmotic-pressure controlling agent present is a salt.

17. An aqueous pharmaceutical composition according to claim 16 , wherein the salt is sodium chloride.

18. An aqueous pharmaceutical composition according to claim 15 , wherein at least one osmotic-pressure controlling agent present is a water-soluble sugar.

19. An aqueous pharmaceutical composition according to claim 18 , wherein the water-soluble sugar is glucose.

20. An aqueous pharmaceutical composition according to claim 1 , wherein the ciclesonide is present in a concentration of between about 0.01% w/w and about 1% w/w, relative to the total amount of the composition.

21. An aqueous pharmaceutical composition according to claim 1 , wherein the ciclesonide is present in a concentration of between about 0.05% w/w and about 0.5% w/w, relative to the total amount of the composition.

22. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one antiseptic.

23. An aqueous pharmaceutical composition according to claim 22 , wherein at least one antiseptic present is benzalkonium chloride.

24. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one pH controlling agent.

25. An aqueous pharmaceutical composition according to claim 24 , wherein at least one pH controlling agent present is selected from the group consisting of hydrochloric acid and sodium hydroxide.

26. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one preservative.

27. An aqueous pharmaceutical composition according to claim 26 , wherein at least one preservative present is ascorbic acid.

28. An aqueous pharmaceutical composition according to claim 1 , further comprising at least one buffer.

29. An aqueous pharmaceutical composition according to claim 28 , wherein at least one buffer present is selected from the group consisting of phosphoric acid and salts thereof.

30. An aqueous pharmaceutical composition according to claim 1 , further comprising

(a) at least one pH controlling agent, and

(b) at least one antiseptic or at least one preservative.

31. An aqueous pharmaceutical composition according to claim 24 , wherein the at least one pH controlling agent is hydrochloric acid.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
SECURITY INTEREST Recorded Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT Recorded Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
RELEASE OF SECURITY INTEREST Recorded Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
SECURITY INTEREST Recorded Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
SECURITY INTEREST Recorded Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
CHANGE OF NAME Recorded Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
CHANGE OF NAME Recorded Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
CHANGE OF NAME Recorded Feb 13, 2003
From: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
To: ALTANA PHARMA AG
Reel/Frame 013751/0522 →
CHANGE OF NAME Recorded Aug 7, 2002
From: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
To: ALTANA PHARMA AG
Reel/Frame 013169/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2002
From: NAGANO, ATSUHIRO; NISHIBE, YOSHIHISA; TAKANASHI, KAZUYA
To: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Reel/Frame 013085/0285 →